GlassScriptPhysician profile
William H Berlin
NPI 1396881447
$1,376.08
in general payments reported to CMS, 2019-2025
22 companies · $123 in 2025
The $123 reported for 2025 was less than what a typical Family Medicine provider received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $258 · 2020: $250 · 2021: $248 · 2022: $155 · 2023: $153 · 2024: $189 · 2025: $123.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $465.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $465.06 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $334.76 | 2019-2025 | Farxiga, Airsupra |
| Pfizer INC. | $181.48 | 2020-2025 | |
| Lilly USA, LLC | $161.77 | 2019-2024 | Zepbound, Mounjaro |
| Abbvie INC. | $111.36 | 2021-2022 | |
| Novo Nordisk INC | $79.05 | 2020-2024 | Rybelsus, Ozempic |
| Boehringer Ingelheim Pharmaceuticals, INC. | $77.84 | 2022-2025 | Jardiance |
| Exact Sciences Corporation | $55.59 | 2024-2025 | Cologuard Collection Kit |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $39.54 | 2019-2020 | |
| Merck Sharp & Dohme LLC | $37.10 | 2019 | |
| Otsuka America Pharmaceutical, INC. | $34.59 | 2023 | Rexulti |
| Idorsia Pharmaceuticals US INC | $33.66 | 2022-2023 | Quviviq |
| Astellas Pharma US INC | $30.37 | 2019-2023 | Veozah |
| Amgen INC. | $28.08 | 2022 | |
| Glaxosmithkline, LLC. | $27.89 | 2021-2024 | Shingrix |
| Amarin Pharma, INC. | $25.82 | 2019 |
Show all 22 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Janssen Pharmaceuticals, INC | $24.23 | 2019 | |
| Gebauer Company | $21.81 | 2025 | |
| Endo Pharmaceuticals INC. | $17.23 | 2021 | |
| Alexion Pharmaceuticals, INC. | $14.19 | 2020 | |
| Daiichi Sankyo INC. | $13.66 | 2019 | |
| Biohaven Pharmaceuticals, INC. | $13.57 | 2021 | |
| Phathom Pharmaceuticals, INC. | $12.49 | 2025 | Voquezna |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw William Berlin listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.